Homology Modeling of Human γ-Butyric Acid Transporters and the Binding of Pro-Drugs 5-Aminolevulinic Acid and Methyl Aminolevulinic Acid Used in Photodynamic Therapy

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Baglo, Yan ^a   Gabrielsen, Mari ^b   Sylte, Ingebrigt ^b   Gederaas, Odrun A ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID CARRIER; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BETAINE GAMMA AMINOBUTYRIC ACID TRANSPORTER 1; GAMMA AMINOBUTYRIC ACID TRANSPORTER 1; GAMMA AMINOBUTYRIC ACID TRANSPORTER 2; GAMMA AMINOBUTYRIC ACID TRANSPORTER 3; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CRYSTAL STRUCTURE; DRUG BINDING; DRUG DESIGN; MOLECULAR DOCKING; MOLECULAR MODEL; PHOTODYNAMIC THERAPY; PROTEIN TRANSPORT;

AMINOLEVULINIC ACID; BINDING SITES; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PHOTOCHEMOTHERAPY; PRODRUGS; PROTEIN BINDING; STATIC ELECTRICITY; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 84878755099     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065200     Document Type: Article

References (59)

1. Dougherty TJ, (1984) Photodynamic therapy (PDT) of malignant tumors. Crit Rev Oncol Hematol 2: 83-116.
2. Issa MC, Manela-Azulay M, (2010) Photodynamic therapy: a review of the literature and image documentation. An Bras Dermatol 85: 501-511.
3. Pottier R, Krammer B, Stepp H, Baumgartner R (2006) Photodynamic therapy with ALA, a clinical handbook: RSC Publishing.
4. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, et al. (1997) 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79: 2282-2308.
5. Scott J (1955) The biosynthesis of porphyrins and porphyrin metabolism. Ciba Foundation symposium Churchill, London: p54.
6. Schoenfeld N, Epstein O, Lahav M, Mamet R, Shaklai M, et al. (1988) The heme biosynthetic pathway in lymphocytes of patients with malignant lymphoproliferative disorders. Cancer Lett 43: 43-48.
7. Di Venosa G, Fukuda H, Batlle A, Macrobert A, Casas A, (2006) Photodynamic therapy: regulation of porphyrin synthesis and hydrolysis from ALA esters. J Photochem Photobiol B 83: 129-136.
8. Grapengiesser S, Ericson M, Gudmundsson F, Larko O, Rosen A, et al. (2002) Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 27: 493-497.
9. Kasche A, Luderschmidt S, Ring J, Hein R, (2006) Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J Drugs Dermatol 5: 353-356.
10. Morton CA, McKenna KE, Rhodes LE, (2008) Guidelines for topical photodynamic therapy: update. Br J Dermatol 159: 1245-1266.
11. Gholam P, Weberschock T, Denk K, Enk A, (2011) Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. Dermatology 222: 358-362.
12. Moloney FJ, Collins P, (2007) Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol 157: 87-91.
13. Steinbauer JM, Schreml S, Babilas P, Zeman F, Karrer S, et al. (2009) Topical photodynamic therapy with porphyrin precursors-assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci 8: 1111-1116.
14. Rud E, Gederaas O, Hogset A, Berg K, (2000) 5-aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol 71: 640-647.
15. Gederaas OA, Holroyd A, Brown SB, Vernon D, Moan J, et al. (2001) 5-Aminolaevulinic acid methyl ester transport on amino acid carriers in a human colon adenocarcinoma cell line. Photochem Photobiol 73: 164-169.
16. Novak B, Schulten R, Lubbert H, (2011) delta-Aminolevulinic acid and its methyl ester induce the formation of Protoporphyrin IX in cultured sensory neurones. Naunyn Schmiedebergs Arch Pharmacol 384: 583-602.
17. Schulten R, Novak B, Schmitz B, Lubbert H (2012) Comparison of the uptake of 5-aminolevulinic acid and its methyl ester in keratinocytes and skin. Naunyn Schmiedebergs Arch Pharmacol.
18. Rodriguez L, Batlle A, Di Venosa G, Battah S, Dobbin P, et al. (2006) Mechanisms of 5-aminolevulinic acid ester uptake in mammalian cells. Br J Pharmacol 147: 825-833.
19. Nelson H, Mandiyan S, Nelson N, (1990) Cloning of the human brain GABA transporter. FEBS Lett 269: 181-184.
20. Borden LA, Dhar TG, Smith KE, Branchek TA, Gluchowski C, et al. (1994) Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site. Receptors Channels 2: 207-213.
21. Borden LA, Smith KE, Gustafson EL, Branchek TA, Weinshank RL, (1995) Cloning and expression of a betaine/GABA transporter from human brain. J Neurochem 64: 977-984.
22. Christiansen B, Meinild AK, Jensen AA, Brauner-Osborne H, (2007) Cloning and characterization of a functional human gamma-aminobutyric acid (GABA) transporter, human GAT-2. J Biol Chem 282: 19331-19341.
23. Saier MH Jr, (2000) A functional-phylogenetic classification system for transmembrane solute transporters. Microbiol Mol Biol Rev 64: 354-411.
24. Chen NH, Reith ME, Quick MW, (2004) Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch 447: 519-531.
25. Jardetzky O, (1966) Simple allosteric model for membrane pumps. Nature 211: 969-970.
26. Tanford C, (1983) Translocation pathway in the catalysis of active transport. Proc Natl Acad Sci U S A 80: 3701-3705.
27. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E, (2005) Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature 437: 215-223.
28. Krishnamurthy H, Gouaux E, (2012) X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature 481: 469-474.
29. Singh SK, Piscitelli CL, Yamashita A, Gouaux E, (2008) A competitive inhibitor traps LeuT in an open-to-out conformation. Science 322: 1655-1661.
30. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, et al. (2004) UniProt: the Universal Protein knowledgebase. Nucleic Acids Res 32: D115-119.
31. Abagyan R, Totrov M, Kuznetsov D, (1994) ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. Journal of Computational Chemistry 15: 488-506.
32. Beuming T, Shi L, Javitch JA, Weinstein H, (2006) A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol Pharmacol 70: 1630-1642.
33. Forrest LR, Tavoulari S, Zhang YW, Rudnick G, Honig B, (2007) Identification of a chloride ion binding site in Na+/Cl-dependent transporters. Proc Natl Acad Sci U S A 104: 12761-12766.
34. Zomot E, Bendahan A, Quick M, Zhao Y, Javitch JA, et al. (2007) Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature 449: 726-730.
35. Abagyan R, Totrov M, (1994) Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol 235: 983-1002.
36. Nemethy G, Gibson KD, Palmer KA, Yoon CN, Paterlini G, et al. (1992) Energy parameters in polypeptides. 10. Improved geometrical parameters and nonbonded interactions for use in the ECEPP/3 algorithm, with application to proline-containing peptides. J Phys Chem 96: 6472-6484.
37. An J, Totrov M, Abagyan R, (2005) Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 4: 752-761.
38. Schapira M, Abagyan R, Totrov M, (2003) Nuclear hormone receptor targeted virtual screening. J Med Chem 46: 3045-3059.
39. Goldberg NR, Beuming T, Soyer OS, Goldstein RA, Weinstein H, et al. (2003) Probing conformational changes in neurotransmitter transporters: a structural context. Eur J Pharmacol 479: 3-12.
40. Laskowski RA, Macarthur MW, Moss DS, Thornton JM, (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 26: 283-291.
41. Colovos C, Yeates TO, (1993) Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 2: 1511-1519.
42. Bowie JU, Luthy R, Eisenberg D, (1991) A method to identify protein sequences that fold into a known three-dimensional structure. Science 253: 164-170.
43. Luthy R, Bowie JU, Eisenberg D, (1992) Assessment of protein models with three-dimensional profiles. Nature 356: 83-85.
44. Anderson CM, Kidd PD, Eskandari S, (2010) GATMD: gamma-aminobutyric acid transporter mutagenesis database. Database (Oxford) 2010: baq028.
45. Dodd JR, Christie DL, (2007) Selective amino acid substitutions convert the creatine transporter to a gamma-aminobutyric acid transporter. J Biol Chem 282: 15528-15533.
46. Skovstrup S, Taboureau O, Brauner-Osborne H, Jorgensen FS, (2010) Homology modelling of the GABA transporter and analysis of tiagabine binding. ChemMedChem 5: 986-1000.
47. Wein T, Wanner KT, (2010) Generation of a 3D model for human GABA transporter hGAT-1 using molecular modeling and investigation of the binding of GABA. J Mol Model 16: 155-161.
48. Pallo A, Simon A, Bencsura A, Heja L, Kardos J, (2009) Substrate-Na+ complex formation: coupling mechanism for gamma-aminobutyrate symporters. Biochem Biophys Res Commun 385: 210-214.
49. Shi L, Quick M, Zhao Y, Weinstein H, Javitch JA, (2008) The mechanism of a neurotransmitter:sodium symporter-inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell 30: 667-677.
50. Brambilla P, Perez J, Barale F, Schettini G, Soares JC (2003) GABAergic dysfunction in mood disorders. Mol Psychiatry 8: 721-737, 715.
51. Wong CG, Bottiglieri T, Snead OC, 3rd (2003) GABA, gamma-hydroxybutyric acid, and neurological disease. Ann Neurol 54Suppl 6: S3-12.
52. Coyle JT, (2004) The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem Pharmacol 68: 1507-1514.
53. Jasmin L, Wu MV, Ohara PT, (2004) GABA puts a stop to pain. Curr Drug Targets CNS Neurol Disord 3: 487-505.
54. Salat K, Kulig K, (2011) GABA transporters as targets for new drugs. Future Med Chem 3: 211-222.
55. Sarup A, Larsson OM, Schousboe A, (2003) GABA transporters and GABA-transaminase as drug targets. Curr Drug Targets CNS Neurol Disord 2: 269-277.
56. Borden LA, Smith KE, Hartig PR, Branchek TA, Weinshank RL, (1992) Molecular heterogeneity of the gamma-aminobutyric acid (GABA) transport system. Cloning of two novel high affinity GABA transporters from rat brain. J Biol Chem 267: 21098-21104.
57. Wu SM, Ren QG, Zhou MO, Peng Q, Chen JY, (2003) Protoporphyrin IX production and its photodynamic effects on glioma cells, neuroblastoma cells and normal cerebellar granule cells in vitro with 5-aminolevulinic acid and its hexylester. Cancer Lett 200: 123-131.
58. Shackley DC, Briggs C, Gilhooley A, Whitehurst C, O'Flynn KJ, et al. (2002) Photodynamic therapy for superficial bladder cancer under local anaesthetic. BJU Int 89: 665-670.
59. Pagliaro J, Elliott T, Bulsara M, King C, Vinciullo C, (2004) Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen's disease: an effective addition to treatment: a pilot study. Dermatol Surg 30: 63-66.